Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
where to buy fat dildos? - LovToyLand.com
Popular Articles

Louisiana House Approves Bill Allowing Providers To Refuse Certain Reproductive Health Services
The Louisiana House on Tuesday voted 82-13 to approve legislation (HB 517) that would allow some health professionals to refuse to provide certain medical services that they object to on religious or moral grounds, the New Orleans Times-Picayune reports.The House-passed bill is an amended version of a measure, introduced by Rep. Bernard LeBas (D), that a House committee rejected earlier this month. The revised bill narrowed the list of procedures that can be denied, and it applies to health providers only in public facilities, not religious health facilities statewide as in the original bill. Under the bill, public health care employees would be allowed to decline to provide abortions or abortifacient drugs. They also would be allowed to refuse participation in embryonic stem cell research or cloning, euthanasia and physician-assisted suicide. Public employees would be immune from civil lawsuits and have job security under the measure.According to the Times-Picayune, Gov. Bobby Jindal"s (R) administration backed the original bill in committee, although state Health Secretary Alan Levine indicated that the bill"s original provisions were too broad. Under the original measure, health care providers would have been allowed to refuse services such as artificial insemination, sterilization, artificial reproductive technologies and "dispensation of drugs affecting the reproductive process." The original measure also would have covered both public and private health care providers (Barrow, New Orleans Times-Picayune, 5/20).Prior to passage, the House approved an amendment to narrow the scope of the bill offered by Rep. John Bel Edwards (D), who said that the original bill"s provisions were not specific enough and could pose problems for private businesses. He also said that the original bill would have posed barriers to patients seeking access to basic treatments and medications (AP/New Orleans Times-Picayune, 5/19). The measure now advances to the state Senate for debate (New Orleans Times-Picayune, 5/20).
diet pills
Increased HIV Risk To Black Gay Men
Black gay men have less choice when it comes to sexual partners than other groups and, as a result, their sexual networks are closely knit. These tightly interconnected networks make the rapid spread of HIV more likely. In a study1) looking at social and sexual mixing between ethnic groups in men who have sex with men, H. Fisher Raymond and Willi McFarland, from the San Francisco Department of Public Health in the US, show that social barriers faced by Black gay men may have a serious impact on their health and well-being. Their findings are published in Springer"s journal AIDS and Behavior.
News of the day
Research-based Pharmaceutical Industry's Health Contribution Presented To Special United Nations Session On Health In Africa And Other Countries
The IFPMA was invited to attend a special session of the United Nations (UN) in Geneva on health in Africa and other least developed countries, organized by the UN Economic and Social Commission (ECOSOC). Michael D. Boyd, Acting Director General of the IFPMA, gave a briefing on the research-based pharmaceutical industry"s contribution to improving health in the developing world, speaking to an audience which included foreign ministers of UN Member States and senior UN officials.
Endocrinology

Researcher Awarded $1.6 Million To Investigate Tumor Suppressor's Role In Breast Cancer

Studies have estimated that five to ten percent of breast cancer cases in the United States are linked to inherited mutations, the most common of which are changes in the BRCA1 or BRCA2 genes. Defects in those genes significantly increase a woman"s chance of getting breast cancer. Aiming to help unlock the mysteries of that critical genetic pathway is Bing Xia, PhD, a scientist at The Cancer Institute of New Jersey (CINJ), who was just awarded $1.6 million from the National Cancer Institute (NCI), a division of the National Institutes of Health. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School. The R01 award will support the work of Dr. Xia, an assistant professor of Radiation Oncology and Pharmacology at UMDNJ-Robert Wood Johnson Medical School, on the functions of PALB2, another gene that has a critical function in the same tumor suppression pathway. BRCA1 and BRCA2 proteins (which are products of the BRCA1 and BRCA2 genes that carry out their functions) are essential to the maintenance and repair of DNA -- the material that makes up one"s genes. These proteins also play important roles in controlling cell growth, particularly after DNA damage. These functions are considered critical to preventing normal cells from becoming cancer cells. Therefore defects in BRCA1 or BRCA2 proteins result in approximately a ten-fold increase of lifetime breast cancer risk. Cancer cells that have non-functional BRCA1 and BRCA2 proteins are unable to repair certain types of DNA damage. Scientists hope to exploit such vulnerability through the use of specifically tailored drugs to kill off such cancer cells. In recent years, Xia and colleagues have discovered that the novel protein PALB2 serves as a major partner of the BRCA2 protein and that it is required in BRCA2 DNA damage response function. By virtue of this essential role in supporting the function of the BRCA2 "tumor suppressor," PALB2 appears to be a tumor suppressor in its own right, according to Xia. He and others have demonstrated that inherited defects in PALB2 cause heightened risk of breast cancer, just as in the case of BRCA2. Xia"s team also recently found that PALB2 also binds the other commonly known breast cancer protein BRCA1, and does so in a way that links the two major breast cancer proteins to form a central breast cancer suppression pathway. In the current project Xia"s team will dig deep into the inner working mechanisms by which PALB2 operates in the cell to support BRCA2 function and connect the two BRCA proteins in DNA repair and cell growth control. They also will generate mouse models of PALB2- and BRCA2-associated breast cancer to study the path of breast cancer development and the characteristics of the tumors. Xia says he is grateful to the NCI for its support and hopes that the results of the study could have a wide-ranging impact. "This research has the potential to yield critical insights into the origin and development of familial breast cancer, and may also shed light on the development of breast cancer in general," he said. "The results and tools generated from this study may also contribute to the rational design of new breast cancer drugs and treatment strategies." The five-year award period runs through June 30, 2014. The Cancer Institute of New Jersey


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009